Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5551
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting ; day:14 ; month:12 ; year:2020 ; pages:1-13
Leukemia ; (14.12.2020), 1-13
- Urheber
-
Modvig, S.
Hallböök, H.
Madsen, H. O.
Siitonen, S.
Rosthøj, S.
Tierens, A.
Juvonen, V.
Osnes, L. T. N.
Vålerhaugen, H.
Hultdin, M.
Matuzeviciene, R.
Stoskus, M.
Marincevic, M.
Lilleorg, A.
Ehinger, M.
Norén-Nystrøm, U.
Toft, N.
Taskinen, M.
Jónsson, O. G.
Pruunsild, K.
Vaitkeviciene, G.
Vettenranta, K.
Lund, B.
Abrahamsson, J.
Porwit, A.
Schmiegelow, K.
Marquart, H. V.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41375-020-01100-5
- URN
-
urn:nbn:de:101:1-2021012118474302197266
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Modvig, S.
- Hallböök, H.
- Madsen, H. O.
- Siitonen, S.
- Rosthøj, S.
- Tierens, A.
- Juvonen, V.
- Osnes, L. T. N.
- Vålerhaugen, H.
- Hultdin, M.
- Matuzeviciene, R.
- Stoskus, M.
- Marincevic, M.
- Lilleorg, A.
- Ehinger, M.
- Norén-Nystrøm, U.
- Toft, N.
- Taskinen, M.
- Jónsson, O. G.
- Pruunsild, K.
- Vaitkeviciene, G.
- Vettenranta, K.
- Lund, B.
- Abrahamsson, J.
- Porwit, A.
- Schmiegelow, K.
- Marquart, H. V.
- SpringerLink (Online service)
Ähnliche Objekte (12)
CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
Precursor B-cell acute lymphoblastic leukemia presenting with isolated skin relapse: a pediatric case report
Clearing MRD positivity with blinatumomab in pediatric B-cell acute lymphoblastic leukemia: insights from droplet digital PCR and flow cytometry
Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction
P359: Improved overall survival and MRD clearance with blinatumomab vs chemotherapy as pre-transplant consolidation in pediatric high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL)
Voyage of Measurable Residual Disease (MRD) Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry
Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France
Association of relapse-linked ARID5B single nucleotide polymorphisms with drug resistance in B-cell precursor acute lymphoblastic leukemia cell lines
Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL
Herstellung von 50 Mio.-, 100 Mio.-, 500 Mio.-, 1 Mrd.-, 5 Mrd.-, 20 Mrd.-, 50 Mrd.-, 100 Mrd.-, 200 Mrd.-, 500 Mrd.-M-Scheinen, 1 Bill.-, 5 Bill.-, 20 Bill.-M-Scheinen
Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma
WM: 10 MRD {EURO} BRASILIANISCHE BILDUNG: 4,5 MRD {EURO}
CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
Precursor B-cell acute lymphoblastic leukemia presenting with isolated skin relapse: a pediatric case report
Clearing MRD positivity with blinatumomab in pediatric B-cell acute lymphoblastic leukemia: insights from droplet digital PCR and flow cytometry
Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction
P359: Improved overall survival and MRD clearance with blinatumomab vs chemotherapy as pre-transplant consolidation in pediatric high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL)
Voyage of Measurable Residual Disease (MRD) Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry
Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France
Association of relapse-linked ARID5B single nucleotide polymorphisms with drug resistance in B-cell precursor acute lymphoblastic leukemia cell lines
Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL
Herstellung von 50 Mio.-, 100 Mio.-, 500 Mio.-, 1 Mrd.-, 5 Mrd.-, 20 Mrd.-, 50 Mrd.-, 100 Mrd.-, 200 Mrd.-, 500 Mrd.-M-Scheinen, 1 Bill.-, 5 Bill.-, 20 Bill.-M-Scheinen
Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma
WM: 10 MRD {EURO} BRASILIANISCHE BILDUNG: 4,5 MRD {EURO}
CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
Precursor B-cell acute lymphoblastic leukemia presenting with isolated skin relapse: a pediatric case report
Clearing MRD positivity with blinatumomab in pediatric B-cell acute lymphoblastic leukemia: insights from droplet digital PCR and flow cytometry
Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction
P359: Improved overall survival and MRD clearance with blinatumomab vs chemotherapy as pre-transplant consolidation in pediatric high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL)
Voyage of Measurable Residual Disease (MRD) Assessment in Multiple Myeloma Using Multiparametric Flow Cytometry
Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France
Association of relapse-linked ARID5B single nucleotide polymorphisms with drug resistance in B-cell precursor acute lymphoblastic leukemia cell lines
Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL
Herstellung von 50 Mio.-, 100 Mio.-, 500 Mio.-, 1 Mrd.-, 5 Mrd.-, 20 Mrd.-, 50 Mrd.-, 100 Mrd.-, 200 Mrd.-, 500 Mrd.-M-Scheinen, 1 Bill.-, 5 Bill.-, 20 Bill.-M-Scheinen
Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma